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Abstract
Background: Safe and effective treatment for chronic inflammatory and neuropathic pain remains
a key unmet medical need for many patients. The recent discovery and description of the transient
receptor potential family of receptors including TRPV1 and TRPA1 has provided a number of
potential new therapeutic targets for treating chronic pain. Recent reports have suggested that
TRPA1 may play an important role in acute formalin and CFA induced pain. The current study was
designed to further explore the therapeutic potential of pharmacological TRPA1 antagonism to
treat inflammatory and neuropathic pain.
Results: The in vitro potencies of HC-030031 versus cinnamaldehyde or allyl isothiocyanate (AITC
or Mustard oil)-induced TRPA1 activation were 4.9 ± 0.1 and 7.5 ± 0.2 μM respectively (IC50).
These findings were similar to the previously reported IC50 of 6.2 μM against AITC activation of
TRPA1 [1]. In the rat, oral administration of HC-030031 reduced AITC-induced nocifensive
behaviors at a dose of 100 mg/kg. Moreover, oral HC-030031 (100 mg/kg) significantly reversed
mechanical hypersensitivity in the more chronic models of Complete Freunds Adjuvant (CFA)-
induced inflammatory pain and the spinal nerve ligation model of neuropathic pain.
Conclusion: Using oral administration of the selective TRPA1 antagonist HC-030031, our results
demonstrated that TRPA1 plays an important role in the mechanisms responsible for mechanical
hypersensitivity observed in inflammatory and neuropathic pain models. These findings suggested
that TRPA1 antagonism may be a suitable new approach for the development of a potent and
selective therapeutic agent to treat both inflammatory and neuropathic pain.
Background
Transient receptor potential ankyrin subfamily, member 1
(TRPA1) is a non-selective cation channel and is the sole
mammalian member that defines the TRPA subfamily.
TRPA1 was shown to be highly expressed in dorsal root,
trigeminal, and nodose ganglia in a specific subpopula-
tion of neurons coexpressing another transient receptor
potential family member, TRPV1, and in the hair cells of
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the inner ear [2-4]. After originally being characterized as
a noxious cold-activated ion channel, several reports
showed that TRPA1 can be activated by a large number of
pungent or irritant compounds, such as cinnamaldehyde,
AITC, acrolein, allicin, and formalin, all of which can
induce acute pain, hyperalgesia, or neurogenic inflamma-
tion in animals and humans [1,5-12]. Additionally, these
compounds have been shown to activate primary afferent
nociceptors and enhance spontaneous and stimulus-
evoked responses of spinal dorsal horn sensory neurons
following peripheral application [8,13-15]. More recently,
the alpha, beta-unsaturated aldehyde, 4-hydroxy-2-none-
nal (HNE) and the electrophilic carbon-containing PGJ2
metabolite, 15dPGJ2, released in response to tissue injury,
inflammation, and oxidative stress, were reported to be
the first endogenous activators of TRPA1 [10,16,17]. Con-
troversy around the apparent promiscuous activation of
TRPA1 by structurally unrelated compounds was dimin-
ished by the finding that the majority of TRPA1 activators
gate the channel through chemical reactivity of their elec-
trophilic groups with some of the nucleophilic cysteine
residues at the N-terminus of the channel [18,19]. In addi-
tion, it was shown that TRPA1 can be gated through
another mode of activation involving its N-terminal EF-
hand calcium binding domain. Two studies suggested that
calcium may directly activate the channel by binding to
the EF-hand domain, a prerequisite for icilin activation of
TRPA1 [20,21].
The above findings that certain pungent and irritant com-
pounds activate TRPA1 led to the suggestion that TRPA1
may be involved in the normal detection of pain. Consist-
ent with such a role, two independent knockout studies
showed that TRPA1-mutant mice do not develop acute
pain or thermal or mechanical hypersensitivity after intra-
plantar injection of bradykinin or AITC [6,22]. In one of
the two studies, TRPA1-mutant mice also showed reduced
sensitivity to intense cold stimulation and a higher thresh-
old of activation in response to painful punctuate
mechanical stimulation [22]. In animal models of inflam-
matory and neuropathic pain, TRPA1 transcripts were up-
regulated in dorsal root ganglia. Furthermore, antisense
knockdown of TRPA1 suppressed cold hypersensitivity in
the SNL (spinal nerve ligation) model and CFA-model of
inflammatory pain in rats [23,24]. Finally, TRPA1 appears
to be sensitized by NGF and Proteinase-Activated Recep-
tor-2 (PAR2), both of which are known to play a role in
inflammatory pain [3,25].
In addition to a potential role in detecting noxious chem-
ical stimuli, there is increasing evidence to suggest that
TRP channels have important roles in mechanoreception.
Vertebrate TRPA1 was proposed as a candidate mechani-
cally-activated channel in hair cells [2]. Mice lacking
TRPA1 function exhibited no hearing deficits although
one study showed a lower sensitivity to cutaneous
mechanical stimulation [22]. Consistent with a possible
role in mechanotransduction, C. elegans  TRPA1 was
shown to be activated by pressure in a heterologous sys-
tem and to play a key role in mediating mechanosensory
functions of this worm [26]. Very recently, Petrus et al.,
(2007) showed that pharmacological inhibition of TRPA1
using intraplantar injection of the selective antagonist,
AP-18, significantly attenuated CFA-induced mechanical
hypersensitivity in TRPA1+/+ but not TRPA1-/- mice [27]. In
addition, intraperitoneal (IP) administration of another
selective TRPA1 antagonist, HC-030031, significantly
reduced flinching in both phases of the formalin response
in vivo [1]. The availability of these reagents provides the
opportunity to better understand the role of this channel
in pain perception.
Given the oral bioavailability of HC-030031, the present
study was undertaken to characterize the antinociceptive
effects of this compound in models of inflammatory and
neuropathic pain through oral administration. We show
that this compound selectively inhibited human TRPA1
activation by cinnamaldehyde with an IC50 of 4.9 μM,
with no significant off-target activity as assessed against a
panel of 48 enzymes, receptors, and transporters known
to be involved in pain signalling. Additionally, we report
that oral dosing of HC-030031 effectively attenuated
mechanical hypersensitivity in models of inflammatory
and neuropathic pain, with no observed effects on acute
heat sensitivity or motor coordination.
Results
HC-030031 selectively inhibits TRPA1 activation by 
cinnamaldehyde and AITC in vitro
The ability of HC-030031 to block TRPA1 activation was
tested in a FLIPR calcium-influx assay using HEK-293 cells
stably expressing human TRPA1. We first tested the TRPA1
agonists cinnamaldehyde and AITC which evoked dose-
dependent calcium influx with EC50 values of 15.9 μM
and 4.3 μM, respectively (data not shown). Concentra-
tions of HC-030031 from 0.3 to 60 μM were incubated
with cells for 10 minutes prior to addition of an EC60 con-
centration of either cinnamaldehyde or AITC. HC-030031
dose-dependently blocked cinnamaldehyde- and AITC-
induced calcium influx with IC50 values of 4.9 and 7.5 μM,
respectively (data not shown). These results are consistent
with previous reports [1]. The selectivity of HC-030031
for TRPA1 was evaluated by testing against 48 different
enzymes, receptors, and transporters (MDS Pharma Serv-
ice, Taipei, Taiwan) that have been reported to modulate
pain signalling. HC-030031 had no significant activity in
any assay at concentrations up to 10 μM (Additional file
1). Previous reports demonstrated that HC-030031 does
not block TRPV1, TRPV3 or TRPV4 activation by capsai-
cin, 2-APB, and 4α-PDD, respectively [1]. In this study, weMolecular Pain 2008, 4:48 http://www.molecularpain.com/content/4/1/48
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expanded these findings and assessed the effect of HC-
030031 on TRPM8. We found that HC-030031 did not
block TRPM8 activation at concentrations up to 30 μM
(data not shown).
Allyl Isothiocyanate-Induced Nocifensive Behaviors are 
Attenuated by HC-030031
The ability of HC-030031 to block the direct activation of
TRPA1 was investigated by examining the potential inhi-
bition of AITC-induced spontaneous hindpaw lifting.
AITC induced significant spontaneous lifting behavior
during the 5 minute observation period following intra-
plantar injection. The mean lifting duration for the vehicle
group (± SEM) was 182.32 s (± 14.97). One hour post-
oral administration (Tmax = 45 minutes after oral admin-
istration in rats; US patent application 2007/0219222
A1), HC-030031 significantly reduced the lifting duration
following 1% AITC injection (ANOVA, p < 0.001, Figure
1). The 100 mg/kg group had an average duration of
123.66 (± 7.44) s and the 300 mg/kg group had an aver-
age duration of 107.52 (± 14.54) s following AITC injec-
tion. Post hoc tests indicated that rats given either 100 or
300 mg/kg HC-030031 had significantly shorter lifting
durations than vehicle treated rats (p < 0.05). These find-
ings are consistent with the results of McNamara and col-
leagues (2007). The average plasma exposure of HC-
030031 in this study was consistent with the levels found
in the CFA and SNL studies; 5.10 (± 0.67) μM for the 100
mg/kg group and 9.74 (± 0.37) μM for the 300 mg/kg
group.
CFA Induced Mechanical Hypersensitivity is Attenuated by 
HC-030031
To examine the role of TRPA1 antagonism in inflamma-
tory pain, we tested HC-030031 using a common measure
of mechanical hypersensitivity, the Randall-Selitto test.
Injection of CFA into the left hindpaw of the rat produced
mechanical hypersensitivity in all subjects at the 24 hour
time point, as evidenced by a significant decrease in
mechanical threshold. Compared to vehicle controls,
both the positive comparator, naproxen, and the TRPA1
antagonist, HC-030031, significantly attenuated the
mechanical hypersensitivity at 1 hr post dosing
(RMANOVA, p < 0.001; Figure 2 panel A). Post hoc tests
found that the naproxen (20 mg/kg) and both 100 and
300 mg/kg HC-030031 groups had significantly higher
mechanical thresholds than the vehicle controls (p <
0.05). As can be seen in Figure 2 (panel B), neither dose of
HC-030031 had an impact on mechanical thresholds for
the uninjected paw. Panel C of Figure 2 demonstrates the
percent reversal [calculated as (post-drug - pre-drug)/
(naïve-pre-drug)*100] for vehicle (5%), naproxen (53%),
and both doses of HC-030031 (28 and 35% for 100 and
300 mg/kg, respectively). In this study, the average plasma
exposure (± SEM) of HC-030031 measured immediately
after testing was 8.23 (± 0.55) μM for the 100 mg/kg
group and 16.33 (± 1.86) μM for the 300 mg/kg group.
Spinal Nerve Ligation Induced Mechanical 
Hypersensitivity is Attenuated by HC-030031
Next, a possible role for TRPA1 in spinal nerve ligation
induced neuropathic pain was investigated using HC-
030031. By 6 weeks post surgery, rats with L5/L6 ligation
displayed significant mechanical hypersensitivity. This
hypersensitivity was significantly reversed by HC-030031
(24 and 41% for 100 and 300 mg/kg, respectively) and
pregabalin (56%; RMANOVA, p < 0.003, Figure 3, panel
A). Post hoc tests indicated that rats given the 300 mg/kg
dose of HC-030031 or pregabalin (20 mg/kg) had signif-
icantly higher mechanical thresholds than vehicle con-
trols (p < 0.05). Panel B of Figure 3 demonstrates the
percent reversal for vehicle, pregabalin, 100 mg/kg and
300 mg/kg HC-030031. The average plasma exposure (±
SEM) of HC-030031 measured immediately after testing
was 6.09 (± 1.25) μM for the 100 mg/kg group and 7.55
(± 0.91) μM for the 300 mg/kg group.
HC-030031 Does Not Alter Locomotor Coordination or 
Thermal Sensitivity
To discount the possibility that TRPA1 antagonism pro-
duced locomotor effects that biased the current results,
rats were dosed with 100 or 300 mg/kg and tested using
the accelerating rotarod test at 1 hr post dose. An ANOVA
found no significant differences between the vehicle and
drug groups (p > 0.05; Figure 4, panel A). This finding is
consistent with other reports for HC-030031 [1]. Lastly,
The effect of TRPA1 antagonism on AITC-induced nocifensive  behaviors Figure 1
The effect of TRPA1 antagonism on AITC-induced 
nocifensive behaviors. Both 100 mg/kg (red bar) and 300 
mg/kg (blue bar) of HC-030031 significantly reduced lifting 
behavior relative to vehicle treated rats given plantar injec-
tion of 1% AITC (white bar; * p, 0.05).
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HC-030031 was tested for its effect on thermal reactivity
using the hot plate test. A RMANOVA performed on the
data found no significant differences between the groups
(p > 0.05), suggesting that TRPA1 antagonism does not
alter basal thermal latencies (Figure 4, panel B). The aver-
age plasma exposure (± SEM) for the rotarod experiment
was 4.31 (± 0.36) μM for the 100 mg/kg group and 10.93
(± 0.44) μM for the 300 mg/kg group. For the hot plate
test, the average plasma exposure (± SEM) was 4.99 (±
0.69) μM for the 100 mg/kg group and 7.21 (± 0.58) μM
for the 300 mg/kg group.
Discussion
In the present study, an orally bioavailable TRPA1 recep-
tor antagonist, HC-030031, was used to further evaluate
the role of TRPA1 receptors in models of inflammatory
and neuropathic pain, and in tests of acute heat sensitivity
and motor coordination. HC-030031 is a selective small
molecule TRPA1 receptor antagonist (human IC50 = 4.9
μM). This compound previously was shown to inhibit
AITC and formalin-evoked TRPA1 currents in vitro, and
inhibit AITC and formalin-induced nociceptive behaviors
in vivo following intraperitoneal dosing[1]. Moreover,
The effect of TRPA1 antagonism on complete Freund's adjuvant induced mechanical hypersensitivity Figure 2
The effect of TRPA1 antagonism on complete Freund's adjuvant induced mechanical hypersensitivity. A. Paw 
withdrawal thresholds for the injected hind paw were assessed using the Randall-Selitto device prior to intraplantar CFA injec-
tions, prior to dosing with vehicle (white bars), 20 mg/kg naproxen (green bars), 100 mg/kg HC-030031 (red bars) or 300 mg/
kg HC-030031 (blue bars), and at one hour post p.o. dosing. Naproxen, 100 mg/kg and 300 mg/kg HC-030031 produced a sig-
nificant attenuation in mechanical hypersensitivity at one hour post dose (*p < 0.05). B. Paw withdrawal thresholds for the non-
injected hind paw assessed using the Randall-Selitto device prior to intraplantar CFA injections, prior to dosing with vehicle 
(white bars), 20 mg/kg naproxen (green bars), 100 mg/kg HC-030031 (red bars) or 300 mg/kg HC-030031 (blue bars), and at 
one hour post p.o. dosing. C. Percent reversal seen at one hour post p.o. dosing with vehicle (white bars), 20 mg/kg naproxen 
(green bars), 100 mg/kg HC-030031 (red bars) or 300 mg/kg HC-030031 (blue bars).
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The effect of HC-030031 on spinal nerve ligation induced mechanical hypersensitivity Figure 3
The effect of HC-030031 on spinal nerve ligation induced mechanical hypersensitivity. A. Fifty percent paw with-
drawal thresholds for the L5/L6 spinal nerve ligated rats assessed using the Dixon up/down method prior to surgery, prior to 
dosing with vehicle (white bars), 20 mg/kg pregabalin (green bars), 100 mg/kg HC-030031 (red bars) or 300 mg/kg HC-030031 
(blue bars), and at one hour post p.o. dosing. Pregabalin and 300 mg/kg HC-030031 produced a significant attenuation in 
mechanical hypersensitivity at one hour post dose (*p < 0.05). B. Percent reversal seen at one hour post p.o. dosing with vehi-
cle (white bars), 20 mg/kg pregabalin (green bars), 100 mg/kg HC-030031 (red bars) or 300 mg/kg HC-030031 (blue bars).
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The effect of HC-030031 on locomotor coordination and thermal sensitivity Figure 4
The effect of HC-030031 on locomotor coordination and thermal sensitivity. A. Neither the 100 mg/kg (red bar) 
nor the 300 mg/kg (blue bar) dose of HC-030031 had a significant impact on the latency to fall off the rotarod during locomo-
tor testing relative to vehicle treated rats (white bar). B. HC-030031 also failed to produce a significant change in thermal 
latencies on the hot plate test for rats dosed at 100 mg/kg (red bar) or 300 mg/kg (blue bar) relative to vehicle treated rats 
(white bar).
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HC-030031 did not display any significant binding to 41
other receptors, ion channels, and transporters nor func-
tional modulation of 7 enzymes that are known to mod-
ulate pain signaling in a target screen (< 40% effect at 10
μM). To confirm in vivo TRPA1 receptor engagement by
HC-030031, effects of this compound on AITC-induced
nociceptive behaviors were determined. When adminis-
tered prior to application of AITC, HC-030031 (100 and
300 mg/kg, p.o.) was found to significantly inhibit AITC-
induced nociceptive behaviors, suggesting that these
doses effectively block TRPA1 receptor activation. Moreo-
ver, the fact that plasma exposures of 5.1 and 9.7 μM were
obtained following oral dosing of 100 and 300 mg/kg,
respectively, supports good oral bioavailability of this
compound in rats.
To examine the role of TRPA1 receptors in inflammatory
pain states, the effect of HC-030031 was evaluated in the
CFA model of inflammatory pain. CFA is a commonly
used rodent model of subchronic inflammatory pain [28],
and in the present study oral administration of HC-
030031 was found to reverse CFA-induced mechanical
hypersensitivity, although efficacy was somewhat less
than that of the positive comparator naproxen. These
results are consistent with a number of previous reports
that have supported a role for TRPA1 receptors in inflam-
matory pain. Using a small molecule TRPA1 receptor
antagonist designated AP18 (mouse IC50  = 4.5 μM),
Petrus et al. (2007) found that intra-paw injection of this
compound completely reversed CFA-induced mechanical
hypersensitivity in wild-type, but not TRPA1 knock-out
mice. Additionally, this compound was found to reverse
partially CFA-induced cold hypersensitivity. In a separate
study using TRPA1 antisense oligodeoxynucleotides,
Obata et al. (2005) found that intrathecal TRPA1 anti-
sense administration inhibited CFA-induced cold allody-
nia, but not heat or mechanical hypersensitivity. Although
it is unclear why effects on mechanical hypersensitivity
were not observed, differences in experimental design
may account for the differing results. For example, Obata
et al. (2005) reported that antisense treatment only
reduced the increased TRPA1 receptor expression follow-
ing CFA injection, and thus greater receptor blockade/
inactivation may be required to inhibit mechanical hyper-
sensitivity. Additionally, differences in the mechanical
stimuli used in these studies, and time of treatment rela-
tive to CFA injection (i.e. development vs maintenance)
may account for the differing results. The contribution of
TRPA1 receptors to inflammatory pain has been suggested
to occur as a consequence of receptor sensitization and/or
activation by a variety of proinflammatory mediators
including bradykinin [5,6,22], protease activated receptor
2 (PAR2) agonists[25], and prostaglandins [16,29,30].
The variety of inflammatory mediators that have been
found to directly activate or indirectly sensitize TRPA1 is
consistent with the results from the present study support-
ing a role for TRPA1 in inflammatory pain.
In addition to effects on inflammatory pain, we found
that oral administration of HC-030031 significantly
reversed tactile hypersensitivity in the SNL model of neu-
ropathic pain. The efficacy observed at the highest dose
tested was comparable to the positive comparator pregab-
alin, which is considered by many to be the first-line treat-
ment for neuropathic pain [31] (for recent review see
Gajraj 2007). TRPA1 has been previously implicated in
neuropathic pain based on the observation that TRPA1
mRNA expression was found to be increased in uninjured
small diameter TrkA+ neurons in the L4 DRG following L5
SNL, and the time course of this upregulation was corre-
lated with the development of cold hypersensitivity [23].
More direct evidence for a role of TRPA1 in the mainte-
nance of cold hypersensitivity in this study was provided
by the observation that acute knock-down of TRPA1 fol-
lowing intrathecal administration of antisense oligodeox-
ynucleotides inhibited cold hypersensitivity. Although
these data suggest an important role for TRPA1 in the
maintenance of pain following neuropathy, the endog-
enous mediators and/or mechanisms responsible for
TRPA1 activation in this case are less clear. In contrast to
the efficacy achieved in the SNL model with pharmacolog-
ical blockade of TRPA1, both mice lacking the function of
TRPA1 and their wildtype littermates developed signifi-
cant mechanical hypersensitivity in the spared nerve
injury (SNI) model. The reason for this discrepancy is
unclear, but one possibility is the upregulation of a pro-
tein that could compensate for the function of TRPA1.
Another possibility is the potential embryonic rewiring of
the neuronal circuitries expressing TRPA1 possibly mask-
ing the phenotype. Finally, while both SNL and SNI mod-
els of neuropathic pain are characterized by heightened
sensitivity to mechanical stimulation, they differ in the
nature of the injury.
In the present study, the plasma concentrations (i.e. ~5.0–
10 μM) that produced antinociceptive efficacy were in a
similar range compared to the in vitro potency values on
TRPA1. This finding was somewhat unusual, since plasma
exposures required to produce antinociceptive efficacy are
typically significantly greater than the in vitro potency val-
ues for analgesic targets. Nevertheless, the fact that HC-
030031 did not display off-target activity in a target
screen, and was found to inhibit AITC-induced nocicep-
tive behaviors at antinociceptive doses, suggests that the
mechanism of action likely involves TRPA1 blockade,
although other mechanisms cannot be ruled out.
While HC-030031 was effective in reversing mechanical
hypersensitivity in models of inflammatory and neuro-
pathic pain, it remains unclear how TRPA1 activation con-Molecular Pain 2008, 4:48 http://www.molecularpain.com/content/4/1/48
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tributes to mechanosensation. Invertebrate and
mammalian TRPA1 receptors were shown to be involved
in mechanoreception [2,26]. However, no data support-
ing a direct activation of this channel by mechanical stim-
ulation is present to date. One possibility is that in
response to mechanical stimulation, damaged/inflamed
tissues release endogenous reactive mediators or respond
by an increase in intracellular calcium, both known to
directly activate TRPA1. Alternatively, inflammatory
mediators may sensitize and/or lower TRPA1 threshold to
mechanical stimulation leading to the development of
mechanical hypersensitivity. Following injury, TRPA1
might enhance the mechanoresponsiveness of other pro-
teins through direct or indirect mechanisms.
The observed efficacy of HC-030031 in inflammatory and
neuropathic pain appears to not involve any coincident
changes in acute heat sensitivity or motor coordination.
Oral administration of HC-030031 failed to have any
effect on hot plate response latencies or rotarod perform-
ance at doses which produced efficacy in the inflamma-
tory and neuropathic pain models. Plasma exposures
from these experiments were comparable to exposures
obtained in the persistent pain model experiments, con-
firming lack of effect at doses that produced efficacy
against inflammatory and neuropathic pain. The ineffec-
tiveness of HC-030031 in the hot plate test is consistent
with previous data showing a lack of noxious heat pheno-
type in TRPA1 knock-out mice and supports the notion
that TRPA1 is not a heat sensor [6,22]. Additionally, the
results from the hot plate experiment are consistent with
the lack of effect of HC-030031 on contralateral, unin-
jured hind paw withdrawal thresholds, in response to
mechanical stimulation, in the CFA model suggesting that
the antinociceptive effects are specific to injury-induced
hypersensitivity. That HC-030031 had no effect on motor
coordination at antinociceptive doses is consistent with a
previous report demonstrating that the efficacy of this
compound is likely specific to effects on sensory transmis-
sion and is not related to motor dysfunction [1].
Conclusion
In summary, the data from the present study have demon-
strated for the first time that an orally administered small
molecule TRPA1 receptor antagonist can effectively
inhibit mechanical hypersensitivity in rodent models of
inflammatory and neuropathic pain at doses that do not
affect acute nociception or motor coordination. These
results further suggest that TRPA1 plays an important role
in nociceptive transmission and support the development
of potential novel analgesics directed against this target.
Methods
Cell Line Generation
Full length human TRPA1 cDNA was purchased from Ori-
gene Technologies (Rockville, MD) and subcloned into
pcDNA5/FRT/V5-His TOPO TA vector (Invitrogen,
Carlsbad, CA). Sequence analysis identified two point
mutations within the coding region of TRPA1 which were
corrected using the QuickChange II site-directed muta-
genesis kit (Stratagene, La Jolla, CA). A HEK-293 cell-line
stably expressing TRPA1 was generated by selection in 100
μg/mL hygromycin B using the Invitrogen Flp-In system.
FLIPR Assay
HEK-293 cells stably expressing human TRPA1 were
plated into 384-well plates at a density of 20,000 cells/
well 24 hours prior to assaying. On the day of assay, cells
were loaded with 4 μM Fluo-4 dye (Invitrogen) and
0.08% pluronic acid (Invitrogen) for 1 hour at room tem-
perature in assay buffer consisting of Hank's balanced salt
solution (Invitrogen) supplemented with 20 mM HEPES
(Invitrogen), 2.5 mM probenecid (Sigma, St. Louis, MO),
and 4% TR-40 (Invitrogen). Calcium influx assays were
performed using the Fluorometric Imaging Plate Reader
(FLIPR) TETRA (Molecular Devices, Sunnyvale, CA). Con-
centration-response curves were generated for the TRPA1
agonists cinnamaldehyde and AITC prior to antagonist
testing so EC60 concentrations could be determined. Titra-
tions of HC-030031 were made from a DMSO stock solu-
tion and DMSO was kept to a constant of 0.4% in the
assay. The antagonist was incubated with the cells for 10
minutes before the addition of an EC60 concentration of
either cinnamaldehyde (18 μM) or AITC (6 μM) and cal-
cium influx was monitored for an additional 10 minutes.
Subjects
Male Sprague-Dawley rats (200–500 g) from Taconic
(New York) were used in all experiments. Animals in all
experiments were allowed ad lib access to food and water
until 16 hrs prior to behavioral testing, at which time the
animals were food deprived. All animal procedures were
approved by the Merck Institutional Animal Care and Use
Committee and were performed in accordance with The
Guide for the Care and Use of Laboratory Animals.
Surgery
To examine the effects of HC-030031 on neuropathic
pain, male Sprague-Dawley rats were given a spinal nerve
ligation (SNL) injury following the procedure of Kim and
Chung (1992) [32]. Briefly, rats were anesthetized with 2–
3% isofluorane and the region on the back at the site of
surgery was shaved and cleaned with topical Betadine and
ethanol. Once an adequate plane of anesthesia was
attained (as assessed by the loss of hindlimb reflexes), a
dorsal midline incision was made from approximately
spinal nerve L3 to S2. A combination of sharp and bluntMolecular Pain 2008, 4:48 http://www.molecularpain.com/content/4/1/48
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dissection probes were used to expose the L6/S1 posterior
interarticular process. The L6 transverse process was visu-
alized and removed and the L4 and L5 spinal nerves were
exposed distal to their emergence from the intervertebral
foramina. The L5 and L6 nerves were tightly ligated with
6-0 silk suture. Following ligation, the muscle and skin
were closed with 4-0 absorbable sutures.
Compounds
HC-030031 (100, 300 mg/kg) was synthesized at Chem-
bridge (San Diego, CA). For all experiments, HC-030031
was suspended in 0.5% Methylcellulose and the drug was
dosed p.o. at a volume of 10 ml/kg. Naproxen (20 mg/kg;
Sigma Aldrich) was dissolved in sterile water and dosed
p.o. to serve as a positive comparator for the CFA experi-
ment. Pregabalin (20 mg/kg) was dissolved in sterile
water and dosed p.o. to serve as a positive comparator for
the neuropathic pain experiment.
Experimental Procedures
Complete Freund's Adjuvant (CFA) Induced Mechanical 
Hypersensitivity
Prior to injection with CFA, rats were given baseline test-
ing to establish mechanical thresholds using the Randall-
Selitto device (Ugo Basile, Switzerland). After baseline
thresholds were established, rats were injected with 100 μl
of 1 mg/ml CFA into the left hindpaw. Twenty-four hrs
later, injected rats were tested for the development of
mechanical hypersensitivity. Once mechanical hypersen-
sitivity had been demonstrated, rats were counterbal-
anced into groups and dosed p.o. with vehicle (0.5%
Methylcellulose), 100 mg/kg or 300 mg/kg of HC-030031
or 20 mg/kg naproxen. Mechanical thresholds were then
reassessed at 1 hr post dosing. Both hindpaws were tested
so that each animal's untreated paw could serve as a con-
trol. In addition, testing was done by an experimenter
blinded to treatment condition. Immediately after the last
test, rats were euthanized with CO2 and both brain and
plasma samples were taken in order to determine the
exposure levels for HC-030031.
Spinal Nerve Ligation Induced Neuropathic Pain
Graded von Frey filaments (Stoelting) were applied to the
hindpaw to assess 50% withdrawal thresholds using the
Dixon up/down method [33] in rats that had received L5/
L6 spinal nerve ligation. For the current study, only rats
that developed mechanical hypersensitivity (as defined as
a 50% mechanical withdrawal threshold of 4 g or less)
were examined. At six weeks post SNL surgery, rats were
given a baseline test and the groups were counterbalanced
prior to being dosed p.o. with vehicle (0.5% Methylcellu-
lose), 100 or 300 mg/kg HC-030031, or 20 mg/kg prega-
balin. One hour after dosing, rats were tested with graded
von Frey filaments to establish 50% withdrawal thresh-
olds. Testing was performed by an experimenter blinded
to treatment condition. Immediately after the last test, rats
were euthanized with CO2 and both brain and plasma
samples were taken in order to determine the exposure
levels for HC-030031.
Allyl Isothiocyanate-Induced Nocifensive Behaviors
The TRPA1 agonist, allyl isothiocyanate (AITC; Fluka) was
used to activate peripheral TRPA1 receptors and elicit
nocifensive behaviors in the rat. Prior parametric work
(data not shown) indicated that 1% AITC was the lowest
concentration that produced a maximal behavioral
response in this assay. Rats were dosed p.o. with vehicle
(0.5% Methylcellulose), 100 or 300 mg/kg of HC-030031
one hour prior to testing and allowed to acclimate to Plex-
iglass observation chambers for 15 minutes prior to AITC
injection. AITC (1%) was injected into the plantar surface
of the left hindpaw and the duration of time spent lifting
the paw was recorded using a stop watch for 5 minutes
post injection by an experimenter blinded to treatment
condition. Immediately after the 5 min observation
period, rats were euthanized with CO2 and both brain and
plasma samples were taken in order to determine the
exposure levels for HC-030031.
Rotarod Test of Locomotor Coordination
The effects of HC-030031 on locomotor coordination
were assessed using the rotarod (IITC Life Science, Wood-
land Hills CA). Prior to testing, each rat was given a base-
line test to establish that there were no preexisting
locomotor deficits. To pass the baseline test, rats were
required to stay on the rotarod for 120 seconds at a speed
of 12 rpm. After the baseline test, rats were dosed p.o. with
vehicle (0.5% Methylcellulose), 100 or 300 mg/kg HC-
030031. One hour post dosing rats were tested for deficits
in locomotor coordination. This test involved accelerating
the speed of the rotarod from 4 rpm to 33 rpm over the
course of a five minute testing interval. Latency to fall off
the rotarod served as the measure. Testing was performed
by an experimenter blinded to treatment condition.
Immediately after testing, rats were euthanized with CO2
and both brain and plasma samples were taken in order to
determine the exposure levels for HC-030031.
Hot Plate Test
To examine the effects of HC-030031 on heat sensitivity,
rats were tested using the hot plate (Ugo Basile, Italy). Rats
were placed on the 52 degree C hot plate and the latency
to lick the hindpaw was measured. Following initial test-
ing, rats were counterbalanced into groups and dosed p.o.
with vehicle (0.5% Methylcellulose), 100 or 300 mg/kg
HC-030031. One hour post dosing, rats were again
assessed on the 52 degree C hot plate to establish changes
in heat sensitivity. Testing was performed by an experi-
menter blinded to treatment condition. Immediately after
testing, rats were euthanized with CO2 and both brain andMolecular Pain 2008, 4:48 http://www.molecularpain.com/content/4/1/48
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plasma samples were taken in order to determine the
exposure levels for HC-030031.
Determination of HC-030031 plasma concentrations
Plasma concentration of HC-030031 was determined
using LC-MS/MS with a heated nebulizer interface (Sciex
4000, Sciex, OT, Canada) in the positive ion mode. Chro-
matography is accomplished with a Phenomenex Luna
C18 (50 × 2 mm, 5 μm) column using reverse phase
mobile phase under fast gradient conditions. Quantita-
tion was based on selected reaction monitoring of the pre-
cursor/product ion pairs for HC-030031 and the internal
standard. Concentrations of HC-030031 were determined
by interpolation from a standard curve prepared in blank
rat plasma.
Statistics
Repeated measures analysis of variance (RMANOVA) was
used to examine changes in reactivity in the CFA-induced
mechanical hypersensitivity and hot plate tests.
RMANOVA utilizing the Greenhouse-Geisser correction
to compensate for unequal error variance was used to ana-
lyze the SNL-mechanical sensitivity data and this test was
followed up with a post hoc Dunnett's test to distinguish
differences between the groups. One way ANOVA was
used to analyze the data from the allyl isothiocyanate
induced nocifensive assay and the rotarod experiment.
Unless otherwise specified, post hoc tests were performed
using the Tukey test. In all cases, statistical significance
was set at p < 0.05.
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